TITLE

Exclusion of Forest CEO Dropped

PUB. DATE
September 2011
SOURCE
Pharmaceutical Representative;Sep2011, Vol. 41 Issue 9, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the efforts to exclude Forest Laboratories Inc. chief executive officer (CEO) Howard Solomon by the Office of the Inspector General (OIG).
ACCESSION #
65353992

 

Related Articles

  • It's Good to Be King. Orr, Deborah // Forbes Asia;5/8/2006, Vol. 2 Issue 8, p69 

    The article provides information on CEO in the U.S. evaluated by "Forbes Asia." Among the factors considered by the periodical in selecting CEO for evaluation include those who are in a company for 20 years and has returned 20% annually to shareholders. Forest Labs started marketing generics...

  • Building on the basics. Koberstein, Wayne // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p46 

    Explains why Forest Laboratories' small presence in the pharmaceutical industry has started to grow at a faster rate relative to the bigger companies in the United States, as discussed by company president and chief executive officer Howard Solomon. Financial performance of the company; Factors...

  • On the mark.  // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p48 

    Presents Forest Laboratories president and chief executive officer Howard Solomon's comments and updates on the company's new drug products launched in 1996. Description of the product; Month launched; Market performance.

  • Forest Laboratories Issues Open Letter to Shareholders.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    A letter is presented from the Howard Solomon, chief executive officer at Forest Laboratories Inc. to the shareholders regarding vote for the highly qualified director nominees of the company.

  • Forest Laboratories Responds to False and Misleading Statements by Carl Icahn.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    A letter is presented from Howard Solomon, chief executive officer at Forest Laboratories Inc. to the shareholders regarding false and misleading statements by investor Carl Icahn.

  • Bitter pill for chief of Forest Labs. ELSTEIN, AARON // Crain's New York Business;8/1/2011, Vol. 27 Issue 31, p0003 

    The article focuses on chief executive officer (CEO) Howard Solomon of Forest Laboratories Inc. It says that Solomon is one of the most successful CEOs which generated an average annual shareholder return of 23 percent. It says that the company developed new drugs with an Alzheimer's treatment...

  • Forest Labs' Saunders Is Named CEO Of Actavis.  // Chain Drug Review;8/11/2014, Vol. 36 Issue 12, p47 

    The article announces the career development of executives including the appointment of Brent Saunders as chief executive officer (CEO) of Forest Laboratories Inc., selection of Stephan Kutzer as CEO of AAIPharma Services Corp. and recruitment of Michael Valentino as chairman of UrgentRX Co.

  • HHS May Push Forest Labs CEO out of Health Care.  // Bioworld Week;4/18/2011, Vol. 19 Issue 16, p1 

    The article reports that Chief Executive Officer Howard Solomon of Forest Laboratories Inc. will be excluded in the federal health care programs as stated by the U.S. Department of Health and Human Services (HHS). It notes that the issue originated from the company's guilty plea to misdemeanor...

  • Rx for Fraud. ZENO, THOMAS E.; DONOVAN, KIMBERLY J. // Criminal Justice;Winter2012, Vol. 26 Issue 4, p4 

    The article reports on the U.S. federal government's fight against health care fraud. The government has proposed to ban Forest Laboratories Chief Executive Officer Howard Solomon from participating in all federal health care programs based on his being a long time corporate chairman....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics